Zentalis Pharmaceuticals Inc
ZNTL1.390USD
+0.050+3.73%
終値 08/04, 16:00（ET）15分遅れの株価
100.01M時価総額
損失額直近12ヶ月PER
詳細情報 Zentalis Pharmaceuticals Inc 企業名
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
企業情報
企業コードZNTL
会社名Zentalis Pharmaceuticals Inc
上場日Apr 03, 2020
最高経営責任者「CEO」Ms. Julie Eastland
従業員数166
証券種類Ordinary Share
決算期末Apr 03
本社所在地10275 Science Center Drive
都市SAN DIEGO
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号92121
電話番号18582634333
ウェブサイトhttps://www.zentalis.com/
企業コードZNTL
上場日Apr 03, 2020
最高経営責任者「CEO」Ms. Julie Eastland
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. David Michael Johnson
Mr. David Michael Johnson
Independent Director
Independent Director
250.42K
+29.87%
Dr. Jan Skvarka, Ph.D.
Dr. Jan Skvarka, Ph.D.
Independent Director
Independent Director
194.95K
+41.94%
Dr. Enoch Kariuki, Pharm.D.
Dr. Enoch Kariuki, Pharm.D.
Independent Director
Independent Director
137.37K
+72.22%
Dr. Ingmar Bruns, M.D.
Dr. Ingmar Bruns, M.D.
Chief Medical Officer
Chief Medical Officer
36.63K
--
Ms. Andrea Paul, J.D.
Ms. Andrea Paul, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.98K
-96.55%
Dr. Luke Walker, M.D.
Dr. Luke Walker, M.D.
Independent Director
Independent Director
--
--
Mr. Karan S. Takhar
Mr. Karan S. Takhar
Independent Director
Independent Director
--
--
Mr. Scott Myers
Mr. Scott Myers
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Julie Eastland
Ms. Julie Eastland
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. David Michael Johnson
Mr. David Michael Johnson
Independent Director
Independent Director
250.42K
+29.87%
Dr. Jan Skvarka, Ph.D.
Dr. Jan Skvarka, Ph.D.
Independent Director
Independent Director
194.95K
+41.94%
Dr. Enoch Kariuki, Pharm.D.
Dr. Enoch Kariuki, Pharm.D.
Independent Director
Independent Director
137.37K
+72.22%
Dr. Ingmar Bruns, M.D.
Dr. Ingmar Bruns, M.D.
Chief Medical Officer
Chief Medical Officer
36.63K
--
Ms. Andrea Paul, J.D.
Ms. Andrea Paul, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.98K
-96.55%
Dr. Luke Walker, M.D.
Dr. Luke Walker, M.D.
Independent Director
Independent Director
--
--
収益内訳
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2019
FY2018
データなし
地域別USD
会社名
収益
比率
United States
0.00
0.00%
事業別
地域別
データなし
株主
更新時刻: Wed, Jul 23
更新時刻: Wed, Jul 23
株主統計
種類
株主統計
株主統計
比率
Matrix Capital Management Company, LP
19.40%
Walters (William T)
9.80%
BlackRock Institutional Trust Company, N.A.
5.33%
The Vanguard Group, Inc.
4.53%
Millennium Management LLC
4.27%
Other
56.67%
株主統計
株主統計
比率
Matrix Capital Management Company, LP
19.40%
Walters (William T)
9.80%
BlackRock Institutional Trust Company, N.A.
5.33%
The Vanguard Group, Inc.
4.53%
Millennium Management LLC
4.27%
Other
56.67%
種類
株主統計
比率
Investment Advisor/Hedge Fund
33.53%
Investment Advisor
20.08%
Hedge Fund
18.52%
Individual Investor
12.74%
Research Firm
4.62%
Venture Capital
3.66%
Corporation
1.33%
Endowment Fund
0.24%
Family Office
0.13%
Other
5.14%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
373
68.31M
94.93%
-22.23M
2025Q1
386
70.02M
97.36%
-19.46M
2024Q4
379
71.39M
100.17%
-15.78M
2024Q3
373
74.19M
104.47%
-21.21M
2024Q2
365
79.92M
112.67%
-23.64M
2024Q1
360
88.75M
125.22%
-9.75M
2023Q4
361
83.47M
118.17%
-13.77M
2023Q3
361
82.76M
117.68%
-11.58M
2023Q2
361
84.96M
121.10%
+6.07M
2023Q1
342
70.12M
118.05%
-6.08M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Matrix Capital Management Company, LP
13.96M
19.4%
--
--
Mar 31, 2025
Walters (William T)
7.05M
9.8%
+3.05M
+76.25%
Jan 29, 2025
BlackRock Institutional Trust Company, N.A.
3.83M
5.33%
-10.27K
-0.27%
Mar 31, 2025
The Vanguard Group, Inc.
3.26M
4.53%
-10.63K
-0.32%
Mar 31, 2025
Millennium Management LLC
3.07M
4.27%
-711.78K
-18.82%
Mar 31, 2025
Acadian Asset Management LLC
2.67M
3.72%
+1.61M
+150.56%
Mar 31, 2025
Decheng Capital LLC
2.02M
2.81%
-318.33K
-13.62%
Mar 31, 2025
Opaleye Management Inc.
1.99M
2.76%
+217.50K
+12.31%
Mar 31, 2025
Almitas Capital LLC
1.71M
2.38%
+84.03K
+5.16%
Mar 31, 2025
Tang Capital Management, LLC
1.50M
2.08%
+1.50M
--
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
Federated Hermes MDT Small Cap Core ETF
0.07%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Micro-Cap ETF
0.01%
Fidelity Enhanced Small Cap ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
Fidelity Growth Opportunities ETF
0%
T Rowe Price Small-Mid Cap ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
詳細を見る
Federated Hermes MDT Small Cap Core ETF
比率0.07%
Invesco RAFI US 1500 Small-Mid ETF
比率0.01%
iShares Micro-Cap ETF
比率0.01%
Fidelity Enhanced Small Cap ETF
比率0.01%
Invesco Nasdaq Biotechnology ETF
比率0%
Virtus LifeSci Biotech Clinical Trials ETF
比率0%
Fidelity Growth Opportunities ETF
比率0%
T Rowe Price Small-Mid Cap ETF
比率0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
比率0%
ProShares Ultra Nasdaq Biotechnology
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
